Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies.
about
Autoimmune Myopathies: Where Do We Stand?Idiopathic Inflammatory Myopathies: Clinical Approach and ManagementSkeletal muscle fibers express major histocompatibility complex class II antigens independently of inflammatory infiltrates in inflammatory myopathies.Clonal tracking of autoaggressive T cells in polymyositis by combining laser microdissection, single-cell PCR, and CDR3-spectratype analysisInfluence of immune responses in gene/stem cell therapies for muscular dystrophies.Immune and myodegenerative pathomechanisms in inclusion body myositisPancreatic adenocarcinoma-associated polymyositis treated with corticosteroids along with cancer specific treatment: case reportNonimmune mechanisms of muscle damage in myositis: role of the endoplasmic reticulum stress response and autophagy in the disease pathogenesis.Diagnostic protein expression in human muscle biopsies.Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodiesProgressive hypoventilation due to mixed CD8+ and CD4+ lymphocytic polymyositis following tremelimumab - durvalumab treatment.Inclusion body myositis: laser microdissection reveals differential up-regulation of IFN-γ signaling cascade in attacked versus nonattacked myofibers.Immunological tolerance to muscle autoantigens involves peripheral deletion of autoreactive CD8+ T cellsThe physiology of inflammatory myopathies: an overview.Immunological capabilities of skeletal muscle cells.Type 1 interferons and myositis.Polymyositis, invasion of non-necrotic muscle fibres, and the art of repetitionIs statin-induced myositis part of the polymyositis disease spectrum?Problems and solutions in myoblast transfer therapy.Effects of nitric oxide on notexin-induced muscle inflammatory responses.Adipokine gene expression in peripheral blood of adult and juvenile dermatomyositis patients and their relation to clinical parameters and disease activity measuresAnalysis of T cell receptor repertoire of muscle-infiltrating T lymphocytes in polymyositis. Restricted V alpha/beta rearrangements may indicate antigen-driven selection.Brief report: antisynthetase syndrome-associated myocarditisSigns of inflammation in both symptomatic and asymptomatic muscles from patients with polymyositis and dermatomyositis.Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies.Up-regulation of MHC class I expression accompanies but is not required for spontaneous myopathy in dysferlin-deficient SJL/J mice.Skeletal muscle major histocompatibility complex class I and II expression differences in adult and juvenile dermatomyositis.Transient immunosuppressive treatment leads to long-term retention of allogeneic myoblasts in hybrid myofibersIdentification of a novel population of muscle stem cells in mice: potential for muscle regeneration.Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells.Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy.Cytokines in idiopathic inflammatory myopathies.The heart in dermatomyositis and polymyositis.Macrophage plasticity and the role of inflammation in skeletal muscle repairThe NKG2D-IL-15 signaling pathway contributes to T-cell mediated pathology in inflammatory myopathiesImmune mechanisms in the pathogenesis of idiopathic inflammatory myopathies.Cell-lineage regulated myogenesis for dystrophin replacement: a novel therapeutic approach for treatment of muscular dystrophyUpregulation of MHC class I in transgenic mice results in reduced force-generating capacity in slow-twitch muscle.Overexpression of MHC class I heavy chain protein in young skeletal muscle leads to severe myositis: implications for juvenile myositisMyonuclear apoptosis in dystrophic mdx muscle occurs by perforin-mediated cytotoxicity.
P2860
Q26744554-58F69175-E02C-42DB-8A0C-21C723FAED5CQ26744705-F5436225-840D-47B5-BF03-85EC7FF29DB6Q30728596-D48FCED0-DCDA-472C-B838-872A881CD42BQ30902237-3E227DEF-7079-4C97-931A-E225495223D3Q33736192-511698D5-60FF-4AA7-A30E-715FC340847CQ33753870-F316217A-3210-4192-8AE0-013FB9707BF9Q33864271-A89BB3D1-4914-4A44-9D5B-2D54044AD1DAQ33880537-1B6BE1CD-8794-4546-98D4-766575EFE7F5Q33891334-504A479C-F33E-49F4-94EA-C6D1D381EA94Q33912061-61607A0E-35B2-4CE9-AC26-E19EAA47847BQ33913077-0A677B2F-245C-4469-8D6F-D147EAD90BD4Q33998204-C4278723-9F34-47D9-8E95-84A291E9EFD0Q34263314-4D923403-8C81-4BD7-8D78-C50B71A88CA8Q34285764-17F9DABE-5C44-4BD4-A855-42950DC48DF1Q34285772-CD2747B0-F5CA-4B1E-973A-E334EEB07C31Q34350190-901BEADB-95EB-4368-AC98-DB8826AC6812Q34377234-4A791FB3-6A75-4C74-9C6C-384149D48625Q34662975-B2F30B9F-0CDE-402F-BB7A-FAA144D358C3Q34687663-C3EF46D8-637E-4061-BA81-0A579924D140Q34785515-13EB8CF3-0236-4F27-9B44-881F24CDACCAQ35540694-A0B6BC8E-9453-4FAB-AB55-24FEFA86FD15Q35612175-6B8608C3-F5EB-41E5-A63E-DC01A81515D7Q35618761-0A4D360A-DB7D-4E1C-8EE5-9CECE0E4A9BCQ35638447-D0CA7507-50E8-4AA4-A926-3D9EB718425FQ35787731-FAD6CBB4-2189-43E8-BF19-A1D782E0C243Q35788717-FF9430EE-9CF1-41A0-92CF-1F2A6F5BA2D0Q36157111-1EEA517F-124C-484A-895F-4DF0FC9A434DQ36234961-9C4FC463-BBDF-4040-813A-7C07806B39F1Q36324366-8B1978F1-F58C-4894-AD8A-7E0E7BC71CC8Q36371257-D5FD0532-4437-4C15-A20A-7249AFA6DF89Q36403275-1C8FCC37-3856-4B5D-8D4B-706C355E687EQ36504371-71DC4A35-A2F0-4B18-B441-4D3E6D26D6ADQ36596345-E66B81BD-DB86-44BA-9BB0-CF9990B704F7Q36610415-54D88B0F-C8F8-4FE9-BF49-8E1BCD048B81Q36685376-94BDA162-98F1-4B29-A94C-774D24F7612EQ36771917-969FFE80-4475-4625-ADFC-BE724F656EBAQ36953163-9DAC6F8A-B1D9-4522-9F29-2A9DC7AA390EQ37154934-4C700A1F-F26C-485F-9FA8-FF482D9325ACQ37316480-9813A738-EE4F-4D84-9D3C-08E6307B083DQ37368276-58351C0C-D164-4036-AE8D-AE5257B494A8
P2860
Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh-hant
name
Major histocompatibility compl ...... ed cytotoxicity in myopathies.
@en
Major histocompatibility compl ...... ed cytotoxicity in myopathies.
@nl
type
label
Major histocompatibility compl ...... ed cytotoxicity in myopathies.
@en
Major histocompatibility compl ...... ed cytotoxicity in myopathies.
@nl
prefLabel
Major histocompatibility compl ...... ed cytotoxicity in myopathies.
@en
Major histocompatibility compl ...... ed cytotoxicity in myopathies.
@nl
P2093
P1433
P1476
Major histocompatibility compl ...... ed cytotoxicity in myopathies.
@en
P2093
Emslie-Smith AM
P304
P356
10.1016/0046-8177(89)90128-7
P407
P577
1989-03-01T00:00:00Z